55094-52-5Relevant articles and documents
Weinreb Amide Approach to the Practical Synthesis of a Key Remdesivir Intermediate
Xie, Yuanchao,Hu, Tianwen,Zhang, Yan,Wei, Daibao,Zheng, Wei,Zhu, Fuqiang,Tian, Guanghui,Aisa, Haji A.,Shen, Jingshan
, p. 5065 - 5072 (2021/04/12)
Currently, remdesivir is the first and only FDA-approved antiviral drug for COVID-19 treatment. Adequate supplies of remdesivir are highly warranted to cope with this global public health crisis. Herein, we report a Weinreb amide approach for preparing the key intermediate of remdesivir in the glycosylation step where overaddition side reactions are eliminated. Starting from 2,3,5-tri-O-benzyl-d-ribonolactone, the preferred route consisting of three sequential steps (Weinreb amidation, O-TMS protection, and Grignard addition) enables a high-yield (65%) synthesis of this intermediate at a kilogram scale. In particular, the undesirable PhMgCl used in previous methods was successfully replaced by MeMgBr. This approach proved to be suitable for the scalable production of the key remdesivir intermediate.
Compound for treating viral infection and preparation method and application of compound
-
Paragraph 0149-0154, (2021/08/07)
The invention provides a preparation for treating viral infection and pneumovirus subfamily viral infection, a method, a compound as shown in a formula (I) and a method and intermediate for synthesis of the compound as shown in the formula (I).
Novel compound and application thereof
-
Paragraph 0081-0083, (2021/09/08)
The invention relates to a novel compound and application thereof, and also relates to an application of the compound in preparation of antiviral drugs and the like. In particular, AIDS virus is present. Application of hepatitis B virus, paramyxovirus and